In conclusion, antibodies and their derivatives are on the list of most prominent candidates for the treatment of prion diseases [49,50] due to their effectiveness at targeting the PrPC as a reservoir for the prion conversion but also because of their potential to act on multiple and diverse levels in the prion pathogenesis. The gene discussed is PRNP; the disease is prion disease.